News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Abbott Laboratories (ABT) Could Dominate Future Stent Marketplace, Analyst Claims



6/17/2013 8:01:06 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Abbott Labs could have a bright future in the field of interventional cardiology thanks to its innovations in the bioabsorbable stent space. “Abbott could see domination of the future stent industry,” says Dan Carroll, an analyst at Motley Fool. Its Absorb stent is the first device of its kind used to treat coronary artery disease. Made of polylactide, the drug-eluting bioresorbable vascular scaffold has been introduced to the market in over 30 countries but not yet in the United States.

Help employers find you! Check out all the jobs and post your resume.

Read at News Release


comments powered by Disqus
Abbott
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES